A61K38/095

PEPTIDE PHARMACEUTICALS
20220348611 · 2022-11-03 ·

Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

SOLID DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY
20230121000 · 2023-04-20 · ·

A solid dosage form for oral transmucosal delivery of an active pharmaceutical ingredient (API) is disclosed. Also provided are methods of treating a disease with the solid dosage form.

SOLID DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY
20230121000 · 2023-04-20 · ·

A solid dosage form for oral transmucosal delivery of an active pharmaceutical ingredient (API) is disclosed. Also provided are methods of treating a disease with the solid dosage form.

Amelioration and Treatment of Opioid Addiction

Disclosed are compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.

Amelioration and Treatment of Opioid Addiction

Disclosed are compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.

Amelioration and Treatment of Opioid Addiction

Disclosed are compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.

Nanoparticle compositions

Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.

Maternal and fetal intrapartum safety monitor
11628252 · 2023-04-18 ·

In part, the disclosure relates to a safety monitor and related methods to evaluate and manage intrapartum uterine contractions induced or augmented by Pitocin or other contraction inducing agents. The systems and methods include measuring a contraction parameter that may include one or more of frequency, strength, and duration of uterine contractions through a measurement device connected to a monitor. The systems and methods are programmed to stop the pump-based administration of a contraction inducing agent. Various lock out protocols and control over the ability to re-start a given pump are also described herein.

Maternal and fetal intrapartum safety monitor
11628252 · 2023-04-18 ·

In part, the disclosure relates to a safety monitor and related methods to evaluate and manage intrapartum uterine contractions induced or augmented by Pitocin or other contraction inducing agents. The systems and methods include measuring a contraction parameter that may include one or more of frequency, strength, and duration of uterine contractions through a measurement device connected to a monitor. The systems and methods are programmed to stop the pump-based administration of a contraction inducing agent. Various lock out protocols and control over the ability to re-start a given pump are also described herein.

POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS

Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.